James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Humana Inc (HUM), First Solar, Inc. (FSLR) and BHP Billiton Limited (ADR) (BHP) Are 3 of Today’s Worst Stocks

Unfortunately, Thursday couldn't end soon enough for owners of First Solar (FSLR), BHP Billiton (BHP) and Humana (HUM).

CMG Stock: Off-Base Tweet Shows Chipotle Mexican Grill, Inc. Is Still Vulnerable

Chipotle stock has bounced back quite a bit from its intraday low, but how much longer will shares be this easy to up-end ... even if only temporarily?

Why American Airlines Group Inc (AAL), Lloyds Banking Group PLC (LYG) and Netflix, Inc. (NFLX) Are 3 of Today’s Worst Stocks

American Airlines (AAL), Lloyds Banking Group (LYG) and Netflix (NFLX) couldn't win for losing on hump-day of this week.

Valeant Pharmaceuticals Intl Inc: VRX Stock Is NOT Going to $90

Valeant Pharmaceuticals (VRX) received a lot of love on Wednesday, but reality will set back in for VRX stock holders soon enough.

Back-to-Back Downgrades of Netflix, Inc. (NFLX) Stock: Take the Hint

NFLX stock has always been something of a battle ground, but the bears just took control of the skirmish. They may not let up for a while.